Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tazemetostat Hydrobromide

FDA-approved product (tablet, oral), marketed as Tazverik.

Registered studies
3
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Tazemetostat Hydrobromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Follicular lymphoma
  • Neoplasm
  • Sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tazemetostat Hydrobromide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tazemetostat Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tazemetostat Plus CHOP in 1L T-cell Lymphoma

    NCT06692452 · start 2024-12-24

    Registered record
    Registry ID
    NCT06692452
    Conditions
    Lymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
    Interventions
    Tazemetostat; Doxorubicin; Vincristine; Prednisone; Cytoxan; Carmustine; Etoposide; Cytarabine; Melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-12-24
    Completion
    2032-10-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma +1 more
    InterventionTazemetostat; Doxorubicin; Vincristine; Prednisone +5 more
    PhasePhase 2
    Registry statusWithdrawn

  • Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

    NCT05353439 · start 2022-07-27

    Registered record
    Registry ID
    NCT05353439
    Conditions
    Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Recurrent Extensive Stage Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Computed Tomography; Pembrolizumab; Tazemetostat Hydrobromide; Topotecan Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-07-27
    Completion
    2027-03-13
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma +2 more
    InterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Pembrolizumab +2 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

    NCT04557956 · start 2021-08-19

    Registered record
    Registry ID
    NCT04557956
    Conditions
    Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
    Interventions
    Biopsy Procedure; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Tazemetostat Hydrobromide; Trametinib Dimethyl Sulfoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2021-08-19
    Completion
    2027-03-11
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
    InterventionBiopsy Procedure; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test +4 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting